Bristol-Myers Partner Ono Drops as Cancer Drug Data Disappoint

Ono Pharmaceutical Co. shares dropped in Japan trading after its partner Bristol-Myers Squibb Co. released study results for its immune-based therapy Opdivo that fell short of already low expectations in a lung cancer trial that studied wider use of the drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.